Your session is about to expire
What is Auryxia
Tetraferric tricitrate decahydrateThe Generic name of this drug
Treatment SummaryTetraferric tricitrate decahydrate is a medication used to treat high levels of phosphates in the blood and iron deficiency anemia, both of which are seen in adults with chronic kidney disease. The drug was approved by the FDA in 2014 and is also known under the brand name Triferic.
Auryxiais the brand name
Auryxia Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Auryxia
Tetraferric tricitrate decahydrate
2014
1
Approved as Treatment by the FDA
Tetraferric tricitrate decahydrate, also known as Auryxia, is approved by the FDA for 5 uses including Dialysis therapy and Iron Deficiency Anemia .Dialysis therapy
Iron Deficiency Anemia
Chronic Kidney Disease
Not on Dialysis
Hyperphosphataemia
Effectiveness
How Auryxia Affects PatientsTetraferric tricitrate decahydrate is a medicine that contains iron and is used to treat iron deficiency anemia and high levels of phosphate in the blood. The dose can vary from person to person, but it works for a long time to treat anemia and a moderate amount of time to treat hyperphosphatemia. Patients should be aware of the potential risks associated with iron overload when taking this medication.
How Auryxia works in the bodyFerric iron is taken in from the digestive system and changed into ferrous iron. This ferrous iron is stored in the cells and then moved into the blood by a protein called ferroportin 1. In the blood, it binds to transferrin, which carries it to other cells. These cells use the iron to make hemoglobin and other proteins. Some of the ferric iron binds to phosphate in the digestive system, forming an insoluble substance that cannot be absorbed. This substance is then eliminated in the feces, reducing phosphate levels in the blood.
When to interrupt dosage
The recommended measure of Auryxia hinges upon the diagnosed issue, including Not on Dialysis, Dialysis therapy and Chronic Kidney Disease. Dosage is also contingent upon the technique of administration specified in the table below.Condition
Dosage
Administration
Dialysis therapy
210.0 mg, , 8.3 mg
, Oral, Tablet, coated, Tablet, coated - Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral
Hyperphosphataemia
210.0 mg, , 8.3 mg
, Oral, Tablet, coated, Tablet, coated - Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral
Iron Deficiency Anemia
210.0 mg, , 8.3 mg
, Oral, Tablet, coated, Tablet, coated - Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral
Not on Dialysis
210.0 mg, , 8.3 mg
, Oral, Tablet, coated, Tablet, coated - Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral
Chronic Kidney Disease
210.0 mg, , 8.3 mg
, Oral, Tablet, coated, Tablet, coated - Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral
Warnings
Auryxia has one contraindication, and should thus not be administered with any of the conditions mentioned in the following table.Auryxia ContraindicationsCondition
Risk Level
Notes
Iron Overload
Do Not Combine
Common Auryxia Drug Interactions
Drug Name
Risk Level
Description
Technetium Tc-99m oxidronate
Major
Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Technetium Tc-99m oxidronate resulting in a reduced serum concentration and potentially a decrease in efficacy.
3-Aza-2,3-Dihydrogeranyl Diphosphate
Minor
Tetraferric tricitrate decahydrate can cause a decrease in the absorption of 3-Aza-2,3-Dihydrogeranyl Diphosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Calcium Phosphate
Minor
Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Calcium Phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Calcium phosphate dihydrate
Minor
Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Calcium phosphate dihydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Dipotassium phosphate
Minor
Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Dipotassium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Auryxia Toxicity & Overdose RiskOverdosing on iron can cause nausea, vomiting, abdominal pain, diarrhea, blood loss, low blood pressure, throwing up blood, perforation, and infection of the abdomen. Mild overdoses can be treated with supportive care, while more severe cases may require chelation therapy or IV fluids. Taking activated charcoal is not likely to help in iron overdose. The lowest toxic dose of iron in rats has been found to be 1487mg/kg in rats and 1520mg/kg in mice.
Auryxia Novel Uses: Which Conditions Have a Clinical Trial Featuring Auryxia?
121 active clinical trials are exploring the potential of Auryxia to aid in managing Chronic Kidney Disease, Iron deficiency anemia and Non-Dialysis patients.Condition
Clinical Trials
Trial Phases
Chronic Kidney Disease
114 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 4, Phase 3, Early Phase 1
Dialysis therapy
3 Actively Recruiting
Not Applicable, Phase 1
Iron Deficiency Anemia
11 Actively Recruiting
Phase 3, Phase 4, Not Applicable, Phase 2
Hyperphosphataemia
0 Actively Recruiting
Not on Dialysis
0 Actively Recruiting
Auryxia Reviews: What are patients saying about Auryxia?
5Patient Review
9/2/20155Patient Review
9/4/20155Patient Review
2/19/20164.3Patient Review
10/4/2018 I'm kept getting yeast infections since starting this medication, and I wonder if it's because of the Auryxia. That said, my Hgb and Hct levels have increased, so there are some definite positives to taking this medicine even though it's quite expensive.
3.7Patient Review
8/15/2017 I wasn't able to get my phosphorous levels under control, even with the lapband. The pills were too big and I had to have it loosened. Within a few months, my level went from 11.5 to 6.
3Patient Review
4/28/2016 I'm a bit hesitant to keep taking this medication for an extended period of time because of the potential liver damage. Additionally, I was not pleased with the change in stool color.
1Patient Review
8/14/2016 I no longer needed regular iron infusions thanks to this medication. Not only that, but my constipation became less chronic and I had fewer stomach upsets. However, I started getting itchy skin and eyes so I'm going to take a break from Aryuxia for now.
Patient Q&A Section about auryxia
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.What is Auryxia tablet?
"Auryxia can lower the amount of phosphate in the blood for adults with chronic kidney disease who are on dialysis."
Answered by AI
Is Auryxia a generic or brand?
"There is not currently a version of Auryxia that is the same as what is available in the United States. There may be illegal online pharmacies that sell a generic version of Auryxia, but these medications may not be safe."
Answered by AI
What are side effects of Auryxia?
"Auryxia may cause common side effects such as diarrhea, constipation, darker color in your bowel movements, nausea, vomiting, stomach pain, or cough."
Answered by AI
What is Auryxia used for?
"This medication works by binding to phosphate in the foods you eat, which then passes out of your body in your stool. Ferric citrate is a form of iron that is also used to treat low blood levels of iron (anemia) in people with long-term kidney disease who are not on dialysis."
Answered by AI